|
Market Closed -
Nasdaq
04:00:00 2026-10-02 pm EDT
|
5-day change | 1st Jan Change | ||
| 504.73 USD | -0.40% |
|
-4.08% | +11.33% |
| Sep. 28 | UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating | MT |
| Sep. 23 | TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 128B | |||||
| 1,019B | |||||
| 617B | - | ||||
| 464B | |||||
| 356B | |||||
| 333B |
Select your edition
All financial news and data tailored to specific country editions
